Advertisement
UK markets close in 6 hours 14 minutes
  • FTSE 100

    7,823.15
    -53.90 (-0.68%)
     
  • FTSE 250

    19,267.78
    -182.89 (-0.94%)
     
  • AIM

    740.50
    -4.79 (-0.64%)
     
  • GBP/EUR

    1.1681
    -0.0003 (-0.02%)
     
  • GBP/USD

    1.2444
    +0.0005 (+0.04%)
     
  • Bitcoin GBP

    52,010.30
    +2,445.57 (+4.93%)
     
  • CMC Crypto 200

    1,332.25
    +19.62 (+1.49%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CRUDE OIL

    83.14
    +0.41 (+0.50%)
     
  • GOLD FUTURES

    2,399.90
    +1.90 (+0.08%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,672.04
    -165.36 (-0.93%)
     
  • CAC 40

    7,960.34
    -62.92 (-0.78%)
     

Eli Lilly weight loss drug for type-2 diabetes approved by the FDA

Yahoo Finance senior health reporter Anjalee Khemlani details Eli Lilly's type-2 diabetes drug approval by the FDA for use as a weight loss drug.

Video transcript

SEANA SMITH: All right, well, a possible blockbuster in the fight against obesity. Anjalee Khemlani has that story for us. Anjalee.

ANJALEE KHEMLANI: That's right, Seana. Eli Lilly got their diabetes drug approved by the FDA for use as a weight loss drug, and that gives it a little bit of an edge against and a higher dose of version of the drugs from Novo Nordisk. This drug now showed in some studies to give individuals, especially those taking the higher dose of the drug, a weight loss, as much as 20% of their body weight.

ADVERTISEMENT

So, that is really causing quite a stir. There is some concern however, about the long-term impacts of that. Some experts have noted that these drugs are used only for a certain period of time. Also, higher dosages tend to result in higher side effects. So, that's also something to work-- to focus on. But on that point of the eventual weaning off of the drug may result in that reduction of that weight loss as well.

So, it could be just a short-term payoff. However, that being said, it is still something new in the arsenal against obesity. And so, this is really where some of the excitement comes on. And of course, you can see Lilly benefiting from that.

- Very fascinating study. Anjalee Khemlani, appreciate that information.